
Please enable javascript to see more information on speakers
| 11.10am |
Opening remarks
| ||
| 11.15am |
Challenges in formulation development in first-in-human strategies
| ||
| 11.45am |
Evaluating the bioperformance Powder in Capsule formulations for use in PhI
| ||
| 12.15pm |
Phase 0 clinical trials: The future in accelerating drug development?
| ||
| 12.45pm | Lunch | ||
| 1.45pm |
Flexible Phase I | ||
| 2.15pm |
Shortening study timelines to proof of concept using new & innovative study formats
| ||
| 2.45pm |
Strategies for Accelerating Proof of Concept (Fast Track)
| ||
| 3.15pm |
Objective comparison of early clinical development plans and better PoC decision-making
| ||
| 3.45pm | Afternoon refreshments | ||
| 4.15pm |
Exploring valuable tools to accelerate CNS product development: steps towards a mechanistic prediction
| ||
| 4.45pm |
Faster, Smarter Clinical Studies
| ||
| 5.15pm |
Panel session – regulatory environment for early development in combination therapeutics
| ||
| 5.45pm | Closing remarks from the chair | ||
| 5.50pm | Networking drinks reception | ||
Evening Seminar | |||
| 6pm |
How can QT assessment in early studies be improved to provide same level of confidence as the ICH E14 ‘Thorough QT/QTc Study’?
|